RIPK1 and cancer: Jue et al. discovered PK68 as a novel inhibitor of RIPK1 kinase activity, suggested that PK68 can be used in the development of new therapies for the treatment of necroptosis-activated pathologies including inflammatory disorders and cancer metastasis.104